Author

John P. Curfman

Observed names: J Curfman, J P Curfman, John Curfman

Observed institutions: University of Iowa, University of Maryland, Baltimore, Roswell Park Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, North Shore University Hospital, The Ohio State University Wexner Medical Center, University of Alabama at Birmingham, University of Chicago, Duke Medical Center, The Ohio State University

OpenAlex ID: A5088658463

microRNA Modulation of Circadian-Clock Period and Entrainment

2007 · Hai-Ying M. Cheng, Joseph W. Papp, et al. · Neuron · 588

PDF

TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

2011 · Klaus H. Metzeler, Kati Maharry, et al. · Journal of Clinical Oncology · 316

Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score

2013 · Guido Marcucci, Pearlly Yan, et al. · Journal of Clinical Oncology · 151

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

2012 · William Blum, Sebastian Schwind, et al. · Blood · 135

Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias

2010 · William Blum, Rebecca B. Klisovic, et al. · Journal of Clinical Oncology · 87

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia

2012 · Pearlly Yan, David Frankhouser, et al. · Blood · 85

Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia

2015 · J Khalife, H S Radomska, et al. · Leukemia · 80

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia

2014 · C Niederwieser, J Kohlschmidt, et al. · Leukemia · 75

inv(16)/t(16;16) acute myeloid leukemia with non–type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations

2012 · Sebastian Schwind, Colin G. Edwards, et al. · Blood · 52

PDF

Methods for high-throughput MethylCap-Seq data analysis

2012 · Benjamin AT Rodriguez, David Frankhouser, et al. · BMC Genomics · 34

PDF

Enrichment-based DNA methylation analysis using next-generation sequencing: sample exclusion, estimating changes in global methylation, and the contribution of replicate lanes

2012 · Michael P Trimarchi, Mark Murphy, et al. · BMC Genomics · 14

PDF

PrEMeR-CG: inferring nucleotide level DNA methylation values from MethylCap-seq data

2014 · David E. Frankhouser, Mark Murphy, et al. · Bioinformatics · 11

PDF

A scalable, flexible workflow for MethylCap-seq data analysis

2011 · Benjamin Rodriguez, Hok-Hei Tam, et al. · IEEE International Workshop on Genomic Signal Processing and Statistics · 10

Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study

2010 · Klaus H. Metzeler, Kati Maharry, et al. · Blood · 7

Methyl-CpG/MBD2 Interaction Requires Minimum Separation and Exhibits Minimal Sequence Specificity

2016 · Blythe Moreland, Kenji Oman, et al. · Biophysical Journal · 6

PDF

Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML)

2011 · Alison R. Walker, Klaus H. Metzeler, et al. · Blood · 4

Characterization of DNA-protein interactions using high-throughput sequencing data from pulldown experiments

2016 · Blythe Moreland, Kenji Oman, et al. · Bulletin of the American Physical Society · 1

Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.

2012 · William Blum, Rebecca B Klisovic, et al. · Blood · 1

Health on the Hilltop: Wellness in the Refugee Population

2015 · John Curfman · The Knowledge Bank (The Ohio State University)

PDF

Targeting Mir-155 via The NEDD8-Activating Enzyme Inhibitor MLN4924: A Novel Therapeutic Approach For Acute Myeloid Leukemia (AML)

2013 · Jihane C Khalife, Hanna S Radomska, et al. · Blood

Works count: 22

Citation count: 1,657

H-index: 11

I10-index: 13